Literature DB >> 7912304

Termination of pregnancy for maternal toxoplasmosis.

A Berrebi1, W E Kobuch, M H Bessieres, M C Bloom, M Rolland, M F Sarramon, C Roques, A Fournié.   

Abstract

Termination of pregnancy is usually recommended to pregnant women who have infection with Toxoplasma gondii before 26 weeks of pregnancy if the fetus is infected. No prospective studies are available on the outcome if such pregnancies are allowed to continue with anti-parasitic treatment. We prospectively studied 163 mothers with acute toxoplasma infection before 28 weeks of amenorrhoea. All received anti-parasitic treatment with 9 million IU spiramycin orally. 23 also received pyrimethamine and sulphadiazine. All had cordocentesis and regular obstetric ultrasound examinations. The 162 liveborn infants were followed up for 15 to 71 months. 3 fetuses died in utero. 27 of 162 liveborn infants had proven congenital toxoplasmosis: 10 had one or more clinical signs of congenital toxoplasmosis; 5 had isolated or multiple intracranial calcifications; 7 had peripheral chorioretinitis; and 2 had moderate ventricular dilations. All 27 are free from symptoms and have normal neurological development at 15 to 71 months of age. We conclude that in first and second trimester pregnancies with acute fetal toxoplasma infection, the pregnancy need not be interrupted if repeated fetal ultrasound is normal, and antiparasitic treatment is given.

Entities:  

Mesh:

Year:  1994        PMID: 7912304     DOI: 10.1016/s0140-6736(94)91054-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established.

Authors:  R Gilbert; C Dezateux
Journal:  Arch Dis Child       Date:  2006-08       Impact factor: 3.791

2.  Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy.

Authors:  M Wallon; C Liou; P Garner; F Peyron
Journal:  BMJ       Date:  1999-06-05

3.  Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study.

Authors:  Mario Cortina-Borja; Hooi Kuan Tan; Martine Wallon; Malgorzata Paul; Andrea Prusa; Wilma Buffolano; Gunilla Malm; Alison Salt; Katherine Freeman; Eskild Petersen; Ruth E Gilbert
Journal:  PLoS Med       Date:  2010-10-12       Impact factor: 11.069

4.  Toxoplasmosis during pregnancy: a case report and review of the literature.

Authors:  C Giannoulis; B Zournatzi; A Giomisi; E Diza; I Tzafettas
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

5.  Incidence of acute symptomatic toxoplasma retinochoroiditis in south London according to country of birth.

Authors:  R E Gilbert; M R Stanford; H Jackson; R E Holliman; M D Sanders
Journal:  BMJ       Date:  1995-04-22

Review 6.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

7.  Diagnosis of congenital toxoplasmosis by immunoblotting and relationship with other methods.

Authors:  B F Chumpitazi; A Boussaid; H Pelloux; C Racinet; M Bost; A Goullier-Fleuret
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

8.  Diagnostic implications of kinetics of immunoglobulin M and A antibody responses to Toxoplasma gondii.

Authors:  M Gorgievski-Hrisoho; D Germann; L Matter
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

9.  Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns, and impairments, in 3 year old children.

Authors:  Katherine Freeman; Alison Salt; Andrea Prusa; Gunilla Malm; Nicole Ferret; Wilma Buffolano; Dorthe Schmidt; Hooi Kuan Tan; Ruth E Gilbert
Journal:  BMC Pediatr       Date:  2005-07-13       Impact factor: 2.125

10.  A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection.

Authors:  Xue-Lan Li; Hai-Xia Wei; Hao Zhang; Hong-Juan Peng; David S Lindsay
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.